结核分枝杆菌乙胺丁醇耐药机制的研究进展  

Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis

作　　者：王婷[1] 焦伟伟[1] 申阿东[1] Ting Wang Weiwei Jiao Adong Shen(Key Laboratory of Major Diseases in Children and National Key Discipline of Pediatrics （Capital Medical University）, Ministry of Education, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beij＇ing Children＇s Hospital, Capital Medical University, Beijing 100045, China)

机构地区：[1]首都医科大学附属北京儿童医院,北京市儿科研究所,儿童呼吸道感染性疾病研究北京市重点实验室,教育部儿科重大疾病研究重点实验室,北京100045

出　　处：《遗传》2016年第10期910-917,共8页Hereditas（Beijing)

基　　金：国家自然科学基金项目(编号:81271889,30901632)资助~~

摘　　要：耐多药结核病的出现和流行对结核病的防控造成了严重威胁。乙胺丁醇（Ethambutol,EMB）是一线抗结核药物,常与异烟肼、利福平等联合应用,还可用于耐药结核病的治疗。但近年来EMB耐药形势严峻,我国复治结核病患者中EMB耐药率已达17.2%,并呈上升趋势;耐多药结核病患者中,EMB耐药率约为51.3%-66.7%,情况不容乐观。明确EMB耐药的产生机制对于有效防控EMB耐药率的上升、充分发挥EMB的作用十分重要,因此本文对结核分枝杆菌EMB的耐药现状、EMB的作用机制及其耐药产生机制方面的研究进展进行了综述。The occurance and prevalence of multidrug-resistant tuberculosis poses a serious threat to the global tuberculosis control. Ethambutol（EMB） is one of the first-line anti-tuberculosis drugs, which is usually used in combination with isoniazid and rifampicin for treating pan-sensitive tuberculosis, and it can also be used in drug-resistant tuberculosis. However, the situation of EMB resistance is alarmingly high, especially in multi-drug resistant tuberculosis. In China, EMB resistance rate in the previously treated cases was up to 17.2% and showed an increased tendency. What was worse, 51.3%-66.7% of multidrug-resistant tuberculosis cases were resistant to EMB. Thus, it is important to understand the drug resistance mechanism of EMB, which will help to slow down the drug resistance rate of EMB. In this review, we focus on the current status of EMB resistance, the effects of EMB and the mechanisms of EMB resistance in Mycobacterium tuberculosis.

关 键 词：结核分枝杆菌 乙胺丁醇 耐药 

分 类 号：R446.5[医药卫生—诊断学]